Table 3.
Impact of CRUSADE bleeding risk on clinical outcome of ticagrelor versus clopidogrel adjusted by PSM, n (%)
| Outcomes | Moderate-to-high bleeding risk | Low bleeding risk | ||||||
|---|---|---|---|---|---|---|---|---|
| Ticagrelor (n = 189) | Clopidogrel (n = 706) | χ2 values | P | Ticagrelor (n = 590) | Clopidogrel (n = 852) | χ2 values | P | |
| NACE | 17 (9.0) | 30 (4.2) | 6.748 | 0.009 | 24 (4.1) | 49 (5.8) | 2.055 | 0.152 |
| MACCE | 9 (4.8) | 21 (3.0) | 1.470 | 0.225 | 15 (2.5) | 42 (4.9) | 5.233 | 0.022 |
| Death | 3 (1.6) | 8 (1.1) | – | 0.708 | 4 (0.7) | 11 (1.3) | 1.273 | 0.259 |
| MI | 1 (0.5) | 8 (1.1) | – | 0.693 | 4 (0.7) | 7 (0.8) | – | 1.000 |
| Stroke | 1 (0.5) | 1 (0.1) | – | 0.378 | 0 (0.0) | 3 (0.4) | – | 0.274 |
| TVR | 4 (2.1) | 6 (0.8) | – | 0.232 | 9 (1.5) | 23 (2.7) | 2.215 | 0.137 |
| All bleeding | 9 (4.8) | 9 (1.3) | – | 0.006 | 9 (1.5) | 7 (0.8) | 1.574 | 0.210 |
| BARC2-5 | 6 (3.2) | 5 (0.7) | – | 0.015 | 2 (0.3) | 1 (0.1) | – | 0.571 |
| BARC3-5 | 4 (2.1) | 3 (0.4) | – | 0.040 | 2 (0.3) | 0 (0.0) | – | 0.167 |
–: Fisher exact test. PSM: Propensity score matching; NACE: Net adverse clinical event; MACCE: Major adverse cardiac or cerebral events; MI: Myocardial infarction; TVR: Target vessel revascularization; BARC: Bleeding Academic Research Consortium.